Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)

NCT00931840 is registered in ClinicalTrials.gov with Enzon Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00931840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00931840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma (mCRC)
Lead sponsor
Enzon Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2009
Completion date
January 31, 2012
Enrollment
220 (estimated)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer